Trevena, Inc. (NASDAQ:TRVN) Q4 2022 Earnings Call Transcript

Carrie Bourdow : And Doug, let me just say that from my perspective, certainly, I was very excited about the entire data set. But the cognition, the delirium data is extremely interesting to me, right? It’s not an area that we had studied previously in our Phase III studies. We had done the head-to-head study in healthy volunteers earlier, I guess, last year when we announced the results. So this now data set in patients in a real-world setting was very impressive to me. So more to come, I think, on this area for us.

Douglas Tsao : And one quick follow-up. In terms of delirium, does that an onset after a single dose of morphine or is it something that is a result of sort of the repeated use? And if you stop using the morphine just the delirium to see its fairly quickly?

Mark Demitrack : Again, a good question. And as you know, delirium is kind of a final common pathway brain dysfunction event. So in a hospital setting, there are typically multiple factors that are likely at play, the use of an IV opioid being an important but only one of multiple factors. So it really is very specific to a patient as to whether or not altering the drug regimen is going to be the key that will abort the delirium in a particular patient. So that’s — it’s a little bit more complicated because of the multiple factors that are involved. But again, IV opioids are recognized to play an important contributing role amongst other factors in the risk of delirium in a hospitalized patient.

Operator: Thank you. Ladies and gentlemen, that concludes our question-and-answer session. I’ll turn the floor back to Ms. Bourdow for any final comments. Great.

Carrie Bourdow : Thank you. And again, thank you for your questions. As you hear, it was a busy quarter for us, and we’re excited that we’re starting to see initial OLINVYK results from the VOLITION study. We’re continuing to make great progress on TRV045, our novel S1P receptor modulator. We have multiple upcoming milestones, including the regulatory update from Nhwa in the first half of this year that they’re expecting. So we’ll continue to update you as we learn more. Thank you again for tuning in this morning.

Operator: Thank you. This concludes today’s conference. You may disconnect your lines at this time. Thank you for your participation.